A Chinese company, WuXi, linked to the Chinese Communist Party, is responsible for developing one-fourth of America's critical drugs, including main ingredients for multibillion-dollar therapies for cancer, obesity, HIV, and cystic fibrosis. This has raised national security concerns among U.S. lawmakers, prompting legislative actions to disconnect U.S. pharmaceutical interests from Chinese biotech firms. A bill currently before the Senate would prohibit federal purchases of healthcare products from companies that do business with Chinese biotechnology, potentially raising healthcare costs for American patients.